汇丰环球研究发表研究报告指出，康哲药业(00867.HK) 旗下Ruxolitinib乳膏在中国上市，成为首款且唯一获批治疗白癜风的靶向药物，Ruxolitinib展现出良好的疗效，该行预计其2026年销售额将达5亿元人民币(下同)，并于2027年翻倍，维持“买入”评级，目标价由从16.8港元上调至17港元。康哲药业宣布其子公司Dermavon获批在中国推出Ruxolitinib磷酸乳膏，用于治疗...
Source Link汇丰环球研究发表研究报告指出，康哲药业(00867.HK) 旗下Ruxolitinib乳膏在中国上市，成为首款且唯一获批治疗白癜风的靶向药物，Ruxolitinib展现出良好的疗效，该行预计其2026年销售额将达5亿元人民币(下同)，并于2027年翻倍，维持“买入”评级，目标价由从16.8港元上调至17港元。康哲药业宣布其子公司Dermavon获批在中国推出Ruxolitinib磷酸乳膏，用于治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.